Propanc Biopharma, Inc.
PPCB· Nasdaq
PPCBPropanc Biopharma, Inc.
Filed Feb 14, 2022 · 10-Q · 45 days after period end · 0001493152-22-004382
| Metric | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 |
|---|---|---|---|---|
| Net Income | -$799.98K | -$403.64K | -$1.87M | -$1.45M |
| EPS Diluted | -$0.02 | -$0.45 | -$1,250.78 | -$41.33 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Propanc Biopharma, Inc. · CIK 1517681 · Engraved from SEC EDGAR
ended Dec 31, 2021 · filed Feb 14, 2022 · 45 d after period end
